Skip to content
Screener

Pre-Tax Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.92B
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%
SIGA Technologies logo
SIGA TechnologiesSIGA
$14.85M-68.6%
AMP
Amphastar PharmaceuticalsAMPH
$38.54M-2.0%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$70.99M+37.3%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$6.13M

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$229.19M-47.4%
Enterprise value$676.49M-19.5%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss on debt extinguishment(20.5)(20.5)
Other, net(3.7)13.966.0
Total other income (expense), net(41.2)(18.4)(38.3)24.4
Income (loss) before income taxes(166.3)(16.8)(152.9)75.9
Income tax provision (benefit)13.9(4.8)20.519.9
Net income (loss)$(180.2)$(12.0)$(173.4)$56.0
Earnings (loss) per common share
Basic$(3.49)$(0.22)$(3.35)$1.03

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's pre-tax income?
Emergent Biosolutions (EBS) reported pre-tax income of -$166.3M in Q2 2026.
How has Emergent Biosolutions's pre-tax income changed year-over-year?
Emergent Biosolutions's pre-tax income decreased by 889.9% year-over-year, from -$16.8M to -$166.3M.
What is the long-term trend for Emergent Biosolutions's pre-tax income?
Over 3 years (2021 to 2024), Emergent Biosolutions's pre-tax income has grown at a -22.2% compound annual growth rate (CAGR), from $303.2M to -$142.9M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Emergent Biosolutions's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude